Himalaya Livline | Vol 6 | No. 4 | May–Aug 2023 | 11 Chronic active hepatitis DS Syrup/DS Tablet: 2 Teaspoonsful/ Tablets BID for 6 months Early cirrhotic conditions DS Syrup/DS Tablet: 1 Teaspoonful/ Tablet TID for 6 to 12 months statin/antiretroviral treatment and chemotherapy Jaundice and anorexia during pregnancy DS Syrup/DS Tablet: 1 Teaspoonful/ Tablet BID for 8 weeks Nonalcoholic steatohepatitis (NASH) DS Tablet: 1 to 2 Tablets BID As a supportive treatment during hemodialysis DS Syrup/DS Tablet: 1 Teaspoonful/ Tablet BID for 3 to 4 months As an adjuvant to anticancer drugs DS Syrup/DS Tablet: 1 Teaspoonful/ Tablet BID for 4 months Dr Sarva Jeet Singh, MBBS, MD Senior Consultant Chest Physician Ursula District Hospital Kanpur 208001, Uttar Pradesh India steatohepatitis (NASH), and 25% to 40% of the patients with NASH could develop progressive liver fibrosis, ultimately resulting in cirrhosis. Doctor, can lifestyle management help reverse the fatty liver condition? Yes, dietary modifications and weight management could help alleviate fatty liver. Satisfactory reduction in liver fat can be achieved by engaging in regular exercise for 30 to 60 minutes for 3 to 5 days/week and by consuming foods enriched with hypocaloric high fibers, low saturated fats, and high proteins. Additionally, consumption of foods rich in ω-3 fatty acids, polyphenols, and vitamins E and D may be beneficial to protect against NAFLD. Can obesity exacerbate NAFLD? Yes, obesity is an established predisposing factor for NAFLD. The prevalence of NAFLD is known to increase with increasing BMI. Abdominal obesity along with insulin resistance results in the pathologic development of NAFLD because of the overproduction of glucose. Furthermore, release of tumor necrosis factor and leptin by the visceral fat tissues also increase the risk of NAFLD progression. Doctor, what therapeutics do you recommend for the management of fatty liver? I generally prescribe Liv.52 DS to patients diagnosed with NAFLD or NASH. Liv.52 DS is a hepatospecific formulation from Himalaya Wellness Company. The pharmacologic properties of the herbal constituents of Liv.52 DS decrease the uptake of free fatty acids, and thereby reduce fat deposition in the hepatocytes, downregulate inflammatory mediators and bring about a decline in hepatic inflammation, and normalize liver biochemical parameters. Our field correspondents: Hari Madhav Tripathi, Regional Manager Puneet Narayan Singh, Pharma Sales Officer HimalayaWellness Company
RkJQdWJsaXNoZXIy MjAwNDg=